Clinical Trial Update: PEG-Glucocerebrosidase for the Treatment of Gaucher Disease [Phase 1]

View source ↗

Summary

Completion of Phase 1 clinical trials evaluating PEG-Glucocerebrosidase for Gaucher disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• PEG-Glucocerebrosidase (PEGylated glucocerebrosidase)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Gaucher's Disease | Phase 1 | Status: COMPLETED